Previous 10 | Next 10 |
2023-05-10 02:35:15 ET Summary Pacira BioSciences came in with a mixed quarter this week, with a miss vs. consensus at the bottom line. Zilretta sales were $24mm or 15% of total quarterly revenue. Longer term, PCRX does not appear to be creating additional market value from th...
TAMPA, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2023 RBC Capital Markets Global Healthcare Conference at 3:05 PM ET on Tuesday, May 16, 2023 in New York. Live audio of the eve...
2023-05-03 13:04:08 ET Pacira BioSciences, Inc. (PCRX) Q1 2023 Results Conference Call May 03, 2023 08:30 AM ET Company Participants Susan Mesco - Head of IR David Stack - CEO Ron Ellis - Chief Strategy Officer Charles Reinhart - CFO Conference Call Par...
2023-05-03 08:02:19 ET Pacira BioSciences press release ( NASDAQ: PCRX ): Q1 Non-GAAP EPS of $0.53 misses by $0.09 . Revenue of $160.3M (+1.5% Y/Y) beats by $0.88M .Net product sales of $130.4 million for EXPAREL, $24.3 million for ZILRETTA, and $4.0 million for io...
-- EXPAREL continues to outperform elective surgery market with average daily volumes up 6 percent over prior year -- -- Conference call today at 8:30 a.m. ET -- TAMPA, Fla., May 03, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commi...
2023-05-02 13:09:34 ET Pacira BioSciences ( NASDAQ: PCRX ) is scheduled to announce Q1 earnings results on Wednesday, May 3rd, before market open. The consensus EPS Estimate is $0.62 (-3.1% Y/Y) and the consensus Revenue Estimate is $159.42M (+0.9% Y/Y). Over the last ...
TAMPA, Fla., April 26, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results before the open of the U.S. markets on Wednesday, May 3, 2023. Following the release, the company will host a live conference call and web...
TAMPA, Fla. and IRVING, Texas, April 20, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc., the industry leader in its commitment to non-opioid pain management and regenerative health solutions, and the Invited Celebrity Classic, an officially sanctioned PGA TOUR Champions event, today announced ...
TAMPA, Fla., April 19, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the appointment of Christopher Young to the position of Chief Manufacturing Offic...
TAMPA, Fla., April 12, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 22 nd Annual Needham Virtual Healthcare Conference at 10:15 AM ET on Wednesday, April 19, 2023. Live audio of the virtual...
News, Short Squeeze, Breakout and More Instantly...
Pacira BioSciences Inc. Company Name:
PCRX Stock Symbol:
NASDAQ Market:
Pacira BioSciences Inc. Website:
-- Proposed Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment System Rule extends separate payment from ambulatory surgical centers to include the hospital outpatient environment – -- Rule implements the NOPAIN Act, signed into law as part of the Cons...
A look at the top 10 most actives in the United States Ocean Power Technologies Inc. (OPTT) rose 86.1% to $0.514 on volume of 587,366,807 shares NVIDIA Corporation (NVDA) fell 1.3% to $122.67 on volume of 214,038,378 shares Tesla Inc. (TSLA) rose 10.2% to $231.26 on volume of 201,850,947 ...
2024-07-02 14:00:06 ET Oren Livnat from H.C. Wainwright issued a price target of $57.00 for PCRX on 2024-07-02 12:36:00. The adjusted price target was set to $57.00. At the time of the announcement, PCRX was trading at $21.91. The overall price target consensus is at $48...